VivoSeq
Immunology

ANCA-Associated Vasculitis

16

Pipeline Programs↗

11

Active Trials↗

10

Companies Involved↗

ANCA-Associated Vasculitis is an emerging landscape with 16 programs across 10 companies. The most active players are GSK, Sanofi, CanSino Biologics Inc.. 4 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

19/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2CanSino Biologics Inc. logo

CanSino Biologics Inc.

1 program

Phase 2S

Staidson (Beijing) Biopharmaceuticals Co., Ltd

1 program

Phase 3Roche logo

Roche

1 program

Phase 3Takeda logo

Takeda

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

12 of 16 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody319%Protein / enzyme16%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 95% of 19 pipeline programs.

Analysis

Trial Status

18

clinical trials

Recruiting9 · 50%
Completed6 · 33%
Not yet recruiting1 · 6%
Unknown status1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05962840·40 enrolled
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT06983821·36 enrolled
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Recruiting·—·Phase 4·NCT06611696·160 enrolled
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Recruiting·Amgen logoAmgen·Phase 4·NCT06072482·300 enrolled
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05965284·40 enrolled
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Recruiting·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 3·NCT07168161·300 enrolled
A Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05946564·126 enrolled
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT07010250·146 enrolled
Biocollection of Patients With ANCA Associated Vasculitis Diagnosed Within the CERAINO Autoimmune Disease Reference Center, Part of the Global BRAISE Project (B-dependent Rare AutoImmune DiseaSES
Recruiting·UUniversity Hospital, Brest·Preclinical·NCT05364892·100 enrolled
ADVOCATE Extension: Avacopan in AAV
Active, not recruiting·Amgen logoAmgen·Phase 3·NCT04578015·330 enrolled
Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement
Not yet recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT07373262·130 enrolled
Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03069703·96 enrolled
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Completed·Amgen logoAmgen·Phase 2·NCT01363388·67 enrolled
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
Completed·Amgen logoAmgen·Phase 2·NCT02222155·42 enrolled
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Completed·MMassachusetts General Hospital·Phase 4·NCT02169219·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)